化合物 MOPIPP|T60858|TargetMol

價(jià)格	￥13800	￥17500	￥10600
包裝	50mg	100mg	25mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2025-07-28

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 MOPIPP	英文名稱:MOPIPP
CAS:1485521-76-3	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
產(chǎn)品類別: 抑制劑
貨號(hào): T60858

Product Introduction

Bioactivity

名稱	MOPIPP
描述	MOPIPP is a novel indolebased chalcone that can cross the blood-brain barrier. MOPIPP inhibits the tumor progression agaisnt glioblastoma cells. MOPIPP induces cellular vacuolization as well as increases autophagosomes numbers. MOPIPP also triggers methuosis and distrupts glucose uptake and glycolytic metabolism [1] [2] [3].
體外活性	MOPIPP (10 μM; 48 h) induces cellular vacuolization but does not cause cell death in U251 glioblastoma cells， exhibiting characteristics of late endosomes [1] [2]. MOPIPP (10 μM; 24 h) results an increasing LC3 fluorescence associated with the number of autophagosomes and inhibits fusion of autophagosomes with lysosomes [1]. MOPIPP (10 μM; 24 h) increases the amounts of exosomal marker proteins in vesicle fractions recovered from 293T cells [2]. MOMIPP (10 μM; 24 h and 5 h, respectively) causes early disruptions of glucose uptake and glycolytic metabolism, induces methuosis, a form of non-apoptotic cell death, in glioblastoma and other cancer cell lines [3]. MOMIPP (10 μM; 4 h and 24 h) selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL [3]. Immunofluorescence [1] Cell Line: U251 glioblastoma cells Concentration: 10 μM Incubation Time: 24 hours; incubated with 2.5 μg/ml Acridine Orange for 45 min Result: Caused accumulation of autophagosome markers. Increased punctate LC3 fluorescence and suggested an increase in the number of autophagosomes in cells. Western Blot Analysis [3] Cell Line: U251 glioblastoma cells Concentration: 10 μM Incubation Time: 4 and 24 hours Result: Triggered increaseing phosphorylation of Bcl-2 and Bcl-xL, accompanied the activation of JNK.
體內(nèi)活性	MOMIPP (80 mg/kg; i.p.; single dose) readily penetrates the bloodbrain barrier in female Swiss Webster Mice and (80 mg/kg; i.p.; every 24 h; 15 d) is effective in suppressing progression of intracerebral glioblastoma xenografts in female NCR-Foxn1 mice [3]. Animal Model: Intracerebral xenograft model in NCR-Foxn1 mice (female, 7-8 weeks, injected with U251- LUC cells) [3] Dosage: 80 mg/kg Administration: Intraperitoneal injection; every 24 hours for 15 days; monitored tumor progression by BLI on the days 7, 11, 15 Result: Significantly inhibited tumor progression.
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.

關(guān)鍵字： MOPIPP|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （13年）	注冊(cè)資本	566.265100萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 4年

公司成立：13年
注冊(cè)資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

(-)-兒茶素|T13597|TargetMol

￥413

化合物 DAT1|T25290|TargetMol

￥13800

化合物 ASP9521|T4529|TargetMol

￥118